Click on an arrow to view a document. Click on a magnifying glass to search a document. Search Page
  | 2 CFR 215 – Uniform Administrative Requirements for Grants and Agreements | |
| | 2 CFR 220 – Cost Principles for Educational Institutions | |
| | 2 CFR 225 – Cost Principles for State, Local and Indian Tribal Governments | |
| | 21 CFR 1 – General Enforcement Regulations | |
| | 21 CFR 2 – General Administrative Rulings and Decisions | |
| | 21 CFR 3 – Product Jurisdiction | |
| | 21 CFR 5 – Organization | |
| | 21 CFR 7 – Enforcement Policy | |
| | 21 CFR 10 – Administrative Practices and Procedures | |
| | 21 CFR 11 – Electronic Records; Electronic Signatures | |
| | 21 CFR 12 – Formal Evidentiary Public Hearing | |
| | 21 CFR 13 – Public Hearing before a Public Board of Inquiry | |
| | 21 CFR 14 – Public Hearing before a Public Advisory Committee | |
| | 21 CFR 15 – Public Hearing before the Commissioner | |
| | 21 CFR 16 – Regulatory Hearing before the Food and Drug Administration | |
| | 21 CFR 17 – Civil Money Penalties Hearings | |
| | 21 CFR 19 – Standards of Conduct and Conflicts of Interest | |
| | 21 CFR 20 – Public Information | |
| | 21 CFR 21 – Protection of Privacy | |
| | 21 CFR 25 – Environmental Impact Considerations | |
| | 21 CFR 26 – Mutual Recognition | |
| | 21 CFR 50 – Protection of Human Subjects | |
| | 21 CFR 54 – Financial Disclosure by Clinical Investigators | |
| | 21 CFR 56 – Amendments: IRB Registration | |
| | 21 CFR 56 – Institutional Review Boards | |
| | 21 CFR 58 – Good Laboratory Practice for Nonclinical Laboratory Studies | |
| | 21 CFR 60 – Patent Term Restoration | |
| | 21 CFR 99 – Dissemination of Information | |
| | 21 CFR 210 – Withdrawal of Revision | |
| | 21 CFR 300 – General | |
| | 21 CFR 310 – New Drugs | |
| | 21 CFR 312 – Amendments: Charging for Investigational Drugs Under an IND | |
| | 21 CFR 312 – Amendments: Expanded Access | |
| | 21 CFR 312 – Investigational New Drug Application | |
| | 21 CFR 314 – Applications for FDA Approval to Market a New Drug | |
| | 21 CFR 315 – Diagnostic Radiopharmaceuticals | |
| | 21 CFR 316 – Amendments: Expanded Access | |
| | 21 CFR 316 – Orphan Drugs | |
| | 21 CFR 320 – Bioavailability and Bioequivalence Requirements | |
| | 21 CFR 361 – Prescription Drugs for Human Use | |
| | 21 CFR 600 – Biological Products: General | |
| | 21 CFR 601 – Licensing | |
| | 21 CFR 812 – Investigational Device Exemptions | |
| | 21 CFR 814 – Premarket Approval of Medical Devices | |
| | 42 CFR 2a – Protection of Identity | |
| | 42 CFR 3 – Amendments: Patient Safety and Quality Improvement | |
| | 42 CFR 400 – Introduction; Definitions | |
| | 42 CFR 403 – Medicare Special Programs and Projects | |
| | 42 CFR 411 – Exclusions from Medicare | |
| | 42 CFR 417 – HMOs and Health Plans | |
| | 42 CFR 423 – Voluntary Medicare Prescription Drug Benefit | |
| | 42 CFR 424 – Conditions for Medicare Payment | |
| | 42 CFR 489.12 – Federal Patient Self-Determination Act | |
| | 42 CFR 1001 - Program Integrity – Medicare and State Health Care Programs | |
| | 45 CFR 46 – Amendments: IRB Registration | |
| | 45 CFR 46 – Protection of Human Subjects | |
| | 45 CFR 60 – National Practitioner Data Bank | |
| | 45 CFR 61 – Healthcare Integrity and Protection Data Bank | |
| | 45 CFR 74 – Institutions of Higher Education, etc. | |
| | 45 CFR 76 – Governmentwide Debarment and Suspension | |
| | 45 CFR 92 – State, Local and Tribal Governments | |
| | 45 CFR 160 – General Administrative Requirements | |
| | 45 CFR 162 – Administrative Requirements | |
| | 45 CFR 164 – Security and Privacy | |
